Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?

BMC Pediatrics
William P HausdorffLode Schuerman

Abstract

Introduction of the 7-valent pneumococcal conjugate vaccine (7vCRM) in several countries has led to a rapid, significant drop in vaccine-type invasive pneumococcal disease (IPD) in immunized children. In the United States and some other countries with high antibiotic use, a subsequent rise in serotype 19A IPD has been taken to indicate that the 19F conjugate in the vaccine provides no cross-protection against the immunologically related 19A. We systematically assessed the clinical efficacy and effectiveness of 19F-containing vaccines against 19A disease or nasopharyngeal carriage by searching English-language articles in the electronic databases PubMed, Current contents, Scopus, and Embase from 1985 to 2008. The vaccine efficacy and effectiveness point estimates were consistently positive for modest protection against 19A IPD and acute otitis media (AOM). However, statistical significance was not reached in any individual study. No consistent impact of 7vCRM on 19A nasopharyngeal colonization could be detected. These findings are discussed in context of immunogenicity analyses indicating that 7vCRM induces functionally active anti-19A antibodies after the booster dose, and that other 19F-containing vaccine formulations may elic...Continue Reading

References

Oct 20, 1993·JAMA : the Journal of the American Medical Association·J C ButlerR R Facklam
Sep 9, 1999·The Journal of Infectious Diseases·N MbelleK P Klugman
Feb 15, 2001·The New England Journal of Medicine·J EskolaUNKNOWN Finnish Otitis Media Study Group
May 2, 2003·The New England Journal of Medicine·Cynthia G WhitneyUNKNOWN Active Bacterial Core Surveillance of the Emerging Infections Program Network
Nov 4, 2005·The Journal of Infectious Diseases·Rekha PaiUNKNOWN Active Bacterial Core Surveillance Team
Apr 7, 2006·The New England Journal of Medicine·Moe H KyawUNKNOWN Active Bacterial Core Surveillance of the Emerging Infections Program Network
Jun 8, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eugene V MillarMathuram Santosham
Feb 9, 2008·Emerging Infectious Diseases·Eun Hwa ChoiHoan Jong Lee
Mar 5, 2008·The Pediatric Infectious Disease Journal·Sarah Y ParkThomas W Hennessy
Apr 19, 2008·The Journal of Infectious Diseases·Matthew R MooreBernard Beall
Jun 4, 2008·The Pediatric Infectious Disease Journal·Keith P KlugmanElizabeth M Molyneux
Sep 11, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eugene V MillarKatherine L O'Brien
Oct 30, 2009·Expert Review of Vaccines·Roman Prymula, Lode Schuerman
Feb 4, 2010·The Pediatric Infectious Disease Journal·Geneviève DeceuninckGaston De Serres

❮ Previous
Next ❯

Citations

Aug 14, 2012·Indian Pediatrics·UNKNOWN Indian Academy of Pediatrics Committee on Immunization (IAPCOI)
Dec 30, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Heather J AdamGeorge G Zhanel
Apr 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter R Paradiso
Apr 17, 2013·American Journal of Respiratory and Critical Care Medicine·Blanca E Gonzalez, Michael R Jacobs
Jun 19, 2014·PloS One·Johanna M JefferiesStuart C Clarke
Oct 27, 2011·Journal of Medical Economics·Gerhart KnererDavid Pearce
Oct 1, 2014·Expert Review of Vaccines·William P HausdorffRichard A Adegbola
Mar 3, 2012·Expert Review of Vaccines·Amy Sarah GinsburgMark R Alderson
Dec 17, 2014·Expert Opinion on Biological Therapy·Mairi Vella, David Pace
Nov 5, 2013·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Pak-Leung HoSusan S Chiu
Oct 17, 2012·Paediatric Respiratory Reviews·Sam Mehr, Nicholas Wood
May 6, 2015·BMC Infectious Diseases·Mark van der LindenMatthias Imöhl
May 21, 2011·Vaccine·Mercedes Macias ParraWilliam P Hausdorff
Oct 14, 2014·Frontiers in Immunology·Michael R YeamanJohn P Hennessey
Aug 1, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Lena Petrova SetchanovaVanio Mitev
Nov 1, 2013·BMC Public Health·Jorge Alberto GomezOleksandr Topachevskyi
Jul 28, 2016·Human Vaccines & Immunotherapeutics·Lijoy VargheseBernard Hoet

❮ Previous
Next ❯

Software Mentioned

Scopus

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.